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Introduction
Aberrant expression or function of histone deacetylases (HDACs) have been implicated in hematopoietic malignancies (1) . Although HDAC inhibition (HDACi) induces tumor cell death while leaving normal cells relatively unaffected, the underlying mechanism(s) behind this remain unclear. Changes in expression of survival genes were observed following HDACi (1); however, whether these alterations resulted from hyper-acetylation of promoters or altered expression of transcriptional mediators was not determined. HDACi also affects DNA replication, likely from the inability to deacetylate histones at replication forks (2, 3) .
Myc, an oncogenic transcription factor, is dysregulated in most hematopoietic malignancies (4) . However, untransformed cells undergo apoptosis to counter hyper-proliferative signals from Myc dysregulation. Specifically, Myc overexpression activates the p53 tumor suppressor pathway, eliciting apoptosis (5, 6) . Myc-induced apoptosis also occurs independent of p53 through down-regulation of anti-apoptotic Bcl-2 and Bcl-x L proteins, by an indirect and unclear mechanism (7) (8) (9) . Both pathways become inactivated during tumorigenesis (10) .
Myc transcriptionally activates or represses numerous genes, regulating many cellular processes (11) . Myc represses protein-coding genes by recruiting HDACs and by binding and inhibiting the transcriptional activator Miz-1 (11, 12) . Myc also regulates the expression of noncoding RNA, including microRNA (miRNA) that bind mRNA, typically inhibiting translation (13) . In malignant cells, Myc represses many miRNA while specifically up-regulating others (13, 14) . Although Myc-mediated transcriptional activation has been extensively studied, mechanisms of Myc-mediated repression and their contribution to tumorigenesis are less understood.
Here we describe a previously unknown miRNA-mediated mechanism of Myc-induced Type Culture Collection. OCI-Ly-19 and OCI-Ly-3 cells were cultured in RPMI-1640 containing 10% fetal bovine serum. P493-6 cells from Dr. Dirk Eick (Helmholtz-Zentrum-Muenchen) were cultured as described (15) . Tetracycline (0.1μg/ml; Sigma) was added to cultures of P493-6 cells for 24 hours to turn off MYC expression. Cell lines were obtained between 2001 and 2007 and immediately frozen, so cells were cultured for less than six months. Primary murine pre-B cultures were generated and infected with retrovirus as previously described (5) ; details in Supplemental. Eμ-myc lymphoma cells were previously isolated and maintained as published (5) . Wild-type or p53 -/-murine embryonic fibroblasts (MEFs) were generated and cultured as described (6) . Fibroblasts were transfected using Lipofectamine2000 (Invitrogen). Retroviral infections of fibroblasts were performed as previously reported (6) . Vector/retrovirus details are in Supplemental.
HDAC inhibition and cell growth and apoptosis assays
In vitro experiments utilized 1µM 4-hydroxytamoxifen (4-OHT) or vehicle (EtOH), and 5nM Apoptosis was evaluated by flow cytometry following propidium iodide (sub-G1 DNA) or AnnexinV/7-AAD staining.
Mice
For the in vivo lymphoma experiments, 10-12 weeks old C57Bl/6 (Jackson Laboratory) mice were subcutaneously injected (one flank) with 4x10 6 Eμ-myc lymphoma cells as previously described (16) 
Human tissue
Normal human B-cells were purified from leukoreduction filters (Red Cross) and de-identified fresh spleens using the IMag Human B-Lymphocyte Enrichment Set (BD-Biosciences). Deidentified fresh spleen and frozen lymph nodes were obtained from the Cooperative Human Tissue Network, following Institutional Review Board approval as non-human subject research (#150139). 
Western blotting
Whole cell protein lysates were prepared and Western blotted as reported (6, 17) . Fibroblasts were lysed 48 hours post-transfection. 
Antibodies

Quantitative chromatin immunoprecipitation (qChIP)
qChIP was performed as previously described (18) . Primer sequences and antibodies in Supplemental.
Quantitative real-time PCR (qRT-PCR)
RNA was isolated, cDNA was generated, and SybrGreen (SA-Biosciences) and TaqMan MicroRNA Assays (Applied Biosciences) were used for qRT-PCR (triplicate) to measure mRNA and miRNA, respectively, as previously described (19, 20) . mRNA and miRNA expression were normalized to β-actin and RNU6b levels, respectively, and presented as 2 -ΔΔCt . Primer sequences in Supplemental. Luciferase and β-galactosidase activity was measured as previously described (19) .
Statistics
Student's t-tests were used to statistically evaluate the data in Fig. 1A, 1C , 2D-G, 3D, 3E, 4B-G, 5A-E, 6E, 7A, 7C, 7E, and 7F. Wilcoxon rank-sum tests determined statistical significance for 
Results
HDAC inhibition decreases Bcl-2 and Bcl-x L expression, inducing apoptosis in multiple hematopoietic malignancies
To evaluate the molecular events following HDACi, B-cell lymphomas from Eμ-myc transgenic mice (Myc-driven B-cell lymphoma model; (21) and human Burkitt's lymphoma lines were treated with HDAC inhibitors. Depsipeptide (Depsi, class-I HDACi), RGFP966 (HDAC3i; (22) , RGFP233 (HDAC1/2i), RGFP963 (HDAC1/2/3i), and Panobinostat (pan-HDACi) all decreased cell expansion and number (Fig. 1A, Supplementary Fig. S1A , S1B). Depsi also reduced cell expansion in nine other malignant human hematopoietic lines, including acute myeloblastic leukemia (Kasumi), chronic myelogenous leukemia (K562), acute T-cell leukemia (Jurkat, Loucy), cutaneous T-cell lymphoma (Hut-78, MyLa), diffuse large B-cell lymphoma (Supplementary Fig. S1C ).
Furthermore, HDACi decreased cell viability (Fig. 1A, Supplementary Fig. S1B ) and increased Caspase-3 cleavage (Fig. 1B) , characteristics of apoptosis.
To identify the molecular determinants of HDACi-mediated apoptosis, we assessed expression of crucial pro-survival proteins. Compared to vehicle control-treated cells, HDACi of murine and human B-cell lymphoma cells decreased protein expression of anti-apoptotic Bcl-2 and Bcl-x L , but not Mcl-1 (Fig. 1B, Supplementary Fig. S1D ). Moreover, Depsi treatment also al., manuscript in preparation). This analysis showed no significant expression changes (increased or decreased) at these loci ( Supplementary Fig. S2C ), suggesting a posttranscriptional mechanism is likely responsible for the observed changes in Bcl-2 and Bcl-x L mRNA.
Therefore, we assessed expression of the miR-15 family (miR-15a, -16-1, -195, -497) and let-7a, as these miRNA post-transcriptionally target and negatively regulate Bcl-2 and Bcl-x L expression, respectively, and induce apoptosis in multiple cell types (Supplementary Fig. S3 ; (25) . Consistent with previous reports (14, 26) , miR-15 family and let-7a levels were decreased in human diffuse large B-cell lymphoma (DLBCL) and Burkitt's lymphoma cell lines compared to purified B-cells and normal lymph nodes (Fig. 2B) . Similarly, B-cell lymphomas from Eµ-myc transgenic mice also had reduced levels of these miRNA compared to levels in pre-cancerous Eµ-myc splenocytes and purified B-cells (Fig. 2C) .
Notably, HDACi increased miR-15a and miR-195 (representative miR-15 family members) and let-7a in lymphoma cells (Fig. 2D, Supplementary Fig. S4A, S4B ). miR-31 levels were unaffected, demonstrating not all miRNA were up-regulated with HDACi. All other malignant hematopoietic lines evaluated showed similar results ( Supplementary Fig. S4C ), indicating this HDACi-induced effect is not cell-type specific. Furthermore, with Depsi dose escalation, miRNA levels increased, indicating a dose response to HDACi (Supplementary Fig.   S4D ).
To evaluate whether the miR-15 family and let-7a were being transcribed upon HDACi, we measured primary miRNA transcripts of the miR-15a/16-1 and miR-195/497 clusters and let7a. Following HDACi, these pri-miRNA transcripts increased (Fig. 2E) . We next performed qChIP for RNA polymerase-II phosphorylated on serine 2 (RNAPII-p-Ser2), which is indicative 
Myc transcriptionally up-regulates the miR-15 family and let-7a in untransformed cells
Myc transcriptionally activates specific miRNA, while repressing others in cancer cells (13, 14) . To determine whether Myc mediated the repression of the miR-15 family and let-7a and/or their induction following HDACi, we evaluated untransformed and transformed cells with altered Myc levels. Unexpectedly, in contrast to transformed cells, Myc-overexpressing precancerous Eµ-myc spleens had increased miR-15 family and let-7a transcripts compared to wildtype littermate spleens (Fig. 4A) . miR-31 levels were analogous between genotypes, indicating Myc overexpression selectively increased specific miRNA in non-transformed cells.
We next assessed primary murine pre-B-cells retrovirally expressing MycER, a 4-hydroxytamoxifen (4-OHT)-inducible Myc (27) . Upon MycER activation with 4-OHT, miR-15 family and let-7a levels significantly increased compared to vehicle control-treated pre-B-cells (Fig. 4B ). This increase was analogous to that of miR-20a, a well-known Myc-induced miRNA (13) . Levels of miR-31 were unaffected. Similar results were obtained following MycER activation in untransformed fibroblasts ( Supplementary Fig. S5A ), indicating this effect also occurs in non-hematopoietic cells. Addition of 4-OHT to non-MycER-expressing pre-B-cells or fibroblasts had no effect on miRNA levels ( Supplementary Fig. S5B ). Therefore, Myc does not repress, but instead induces the miR-15 and let-7 families in untransformed cells.
To determine whether Myc was transcriptionally activating the miR-15 and let-7 families in untransformed cells, we utilized a MycER mutant lacking the Myc-Box-II domain (MycΔMBII-ER) essential for Myc-mediated transcriptional activation (11) . Levels of the miR-15 family and let-7a were not induced following MycΔMBII-ER activation in wild-type murine embryonic fibroblasts (MEFs), but were when transcriptionally competent MycER was activated (Fig. 4C) . When primary transcripts of the miR-15a/16-1 and miR-195/497 clusters and let-7a were evaluated, MycER, but not MycΔMBII-ER, induced their expression in MEFs and pre-Bcells (Fig. 4D, 4E ), indicating Myc-mediated transcription was necessary to up-regulate these miRNA.
To assess whether Myc was at the miRNA promoters and whether active transcription was occurring, qChIP was performed. qChIP for Myc in MycER-expressing MEFs revealed enrichment at the promoter regions of the miR-15a/16-1 and miR-195/497 clusters and let-7a following 4-OHT-induced MycER activation (Fig. 4F) . Importantly, RNAPII-p-Ser2 and H3K9K14ac, indicators of active transcription, were also enriched ( 
Myc is required for HDACi-induced miR-15 family and let-7a transcriptional upregulation
To determine the role of Myc in repressing the miR-15 and let-7 families in malignant cells, qChIP was performed on Myc-overexpressing murine and human lymphoma cells. Myc was enriched at the promoters of both miR-15 family clusters and let-7a in both cell lines, but not at upstream regions (Fig. 5A) . ENCODE MYC ChIP-seq data (28) also showed MYC at these promoters in hematopoietic and non-hematopoietic malignancies and non-transformed human cells ( Supplementary Fig. S6A ). Importantly, Myc was enriched at these same loci in both the presence and absence of HDACi (Fig. 5A) . Consistent with Myc-mediated repression of these loci in lymphoma, there was significantly more enrichment of Myc at the promoter regions of the Fig. S6B ).
Myc transcriptionally activates CAD and represses p21 (11) , consistent with the increase in RNAPII-p-Ser2 and H3K9K14ac at CAD and the lack of enrichment at p21 we observed in the lymphoma cells (Fig. 5B) . Neither RNAPII-p-Ser2 nor H3K9K14ac enrichment was detected at promoters of either miR-15 family cluster or let-7a in the lymphomas (Fig. 5B) . Collectively, the data indicate Myc activates miR-15 family and let-7a transcription in untransformed cells, whereas it appears to repress their transcription in transformed cells. Moreover, HDACi of B-cell lymphoma induced the miR-15 family and let-7a to levels similar to those in non-transformed pre-cancerous B-cells overexpressing Myc ( Supplementary Fig. S6C ). Furthermore, the derepression of the miR-15 family and let-7a detected in lymphomas following 6 hours of HDACi did not appear to be due to changes in Myc protein, as Myc levels were similar for at least 12 hours after HDACi (Supplementary Fig. S6D ). Together, our data suggest HDACi converts Myc from a transcriptional repressor into a transcriptional activator in lymphoma.
To test whether Myc was required for HDACi-induced up-regulation of the miR-15 family and let-7a, we utilized the human B-cell lymphoma line, P493-6, that expresses a tetracycline-regulatable MYC (15) . With tetracycline present, MYC levels were significantly reduced and HDACi failed to increase miR-15a, miR-195, or let-7a levels (Fig. 5C ). Only when MYC was expressed did HDACi increase their expression. Therefore, Myc was required to mediate the HDACi-induced up-regulation of the miR-15 family and let-7a. Additionally, irrespective of HDACi, when MYC expression was off, levels of the miR-15 and let-7 families were slightly increased compared to when MYC was expressed, providing additional evidence MYC represses these miRNA in lymphoma. 
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To further assess the requirements of MYC on miR-15 family and let-7a expression, we performed qChIP with P493-6 cells. When Myc was expressed, it was enriched at the miR-15 family and let-7a promoters (Fig. 5D ). Upon HDACi, enrichment of RNAPII-p-Ser2 and H3K9K14ac (marks of active transcription) at miR-15 family and let-7a promoters was only observed in MYC-expressing cells (Fig. 5E) . When MYC was not expressed, a slight enrichment of RNAPII-p-Ser2 and H3K9K14ac was detected at the miR-15 family and let-7a promoters, regardless of HDACi (Fig. 5E ). These data show MYC mediated the repression of the miR-15 family and let-7a and was required for their HDACi-induced transcriptional up-regulation.
Myc transcriptional activity is required to suppress Bcl-2 and Bcl-x L expression
In untransformed cells, Myc suppressed Bcl-2 and Bcl-x L expression, inducing apoptosis through an indirect, unresolved mechanism (7, 8) , purportedly through binding Miz-1 (9).
However, Bcl-2 and Bcl-x L proteins are overexpressed in the majority of Eµ-myc B-cell lymphomas and human lymphomas (8) . Evaluation of Eµ-myc B-cell lymphomas compared to normal B-cells and spleens from pre-cancerous Eµ-myc mice confirmed these results (Fig. 6A) .
In contrast, pre-cancerous Eµ-myc spleens with increased Myc had reduced Bcl-2 and Bcl-x L protein compared to non-transgenic littermate-matched spleens (Fig. 6B) . Mcl-1 and Bax (proapoptotic Bcl-2 family member) were unaffected. Similarly, in MycER-expressing primary pre-B-cells and MEFs, decreases in Bcl-2 and Bcl-x L were detected following MycER activation (Fig. 6C) . No change in Mcl-1 or Bax expression was detected, whereas Bim, a pro-apoptotic Bcl-2 family member up-regulated by Myc (29), was increased upon MycER activation (Fig.   6C ). Therefore, with elevated Myc, non-transformed cells decrease Bcl-2 and Bcl-x L expression, whereas their expression is increased in transformed cells.
Myc associates with the transcription factor Miz-1 through a motif requiring valine 394, 
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reportedly suppressing Bcl-2 (9). To investigate this, MycER harboring a point mutation (V394D) disrupting the Myc:Miz-1 interaction (MycV394D-ER; Supplementary Fig. S7A ) (30) was expressed in wild-type MEFs. Following MycV394D-ER activation with 4-OHT, Bcl-2 and Bcl-x L were suppressed equivalently to cells expressing wild-type MycER, ruling out a Miz-1-mediated mechanism (Fig. 6D) . Analogous data were obtained using p53-null MEFs (Supplementary Fig. S7B ), consistent with prior results in p53-null myeloid and B-cells (7, 8) .
These data reveal a Miz-1-and p53-independent mechanism for Myc-mediated suppression of Bcl-2 and Bcl-x L expression. Moreover, MycV394D-ER effectively induced miR-15 family and let-7a expression (Fig. 6E) , further supporting this miRNA-mediated mechanism of Myc-induced suppression of Bcl-2 and Bcl-x L . Additionally, evaluation of ChIP-seq data for Miz-1 in four human and six murine cell lines/tissues (31-34) showed Miz-1 enrichment at promoters of known Miz-1-regulated genes (e.g., VAMP4) ( Supplementary Fig. S7C ). However, Miz-1 was not enriched at the miR-15 family or let-7a promoters in any of the cell lines/tissues evaluated, indicating Miz-1 does not transcriptionally regulate these miRNA.
To determine whether Myc transcriptional activity is required to decrease Bcl-2 and Bclx L expression in normal cells, wild-type MEFs expressing MycER or the transcriptionally inactive MycΔMBII-ER mutant were evaluated. Following 4-OHT addition, decreased Bcl-2 and Bcl-x L and increased Bim expression were only observed in cells expressing wild-type MycER and not MycΔMBII-ER (Fig. 6F) . Again, Mcl-1 and Bax expression were unaffected. Therefore, Myc-mediated transcriptional activity is necessary for Bcl-2 and Bcl-x L down-regulation.
Myc transcriptionally induces the miR-15 family and let-7a that then target Bcl-2 and
Bcl-x L
We reasoned that defining the Myc-induced mechanism of Bcl-2 and Bcl-x L down- To further validate this mechanism, wild-type MEFs were transfected with modified RNA molecules (Target Protectors) designed to block the miR-15 family or let-7a from binding their specific target sites in the Bcl-2 or Bcl-x L 3'-UTR, respectively. Bcl-2 and Bcl-x L protein increased in wild-type MEFs transfected with Bcl-2 or Bcl-x L Target Protectors, respectively, as endogenous miR-15 family members and let-7a were unable to bind and inhibit their expression (Fig. 7B) . Combining the Bcl-2 Target Protector with miR-15a overexpression, which alone decreased Bcl-2 protein, rescued Bcl-2 protein expression (Fig. 7B) . Then, MycER-expressing fibroblasts were transfected with luciferase reporters, as described above, together with the Bcl-2 or Bcl-x L Target Protectors. In the presence of Bcl-2 or Bcl-x L Target Protectors, little, if any, decrease in luciferase activity was detected following MycER activation (Fig. 7C) . Next, MEFs expressing MycV394D-ER (unable to interact with Miz-1) were transfected with Bcl-2 or Bcl-x L Target Protectors. MycV394D-ER activation decreased Bcl-2 and Bcl-x L protein expression in the absence of any Target Protector (Fig. 7D) . However, levels of Bcl-2 or Bcl-x L were maintained when Target Protectors blocked the miR-15 or let-7 family binding sites, respectively (Fig. 7D) . Therefore, down-regulation of Bcl-2 and Bcl-x L upon Myc activation in untransformed cells was due to induction of the miR-15 family and let-7a that bind the 3'-UTR of Bcl-2 and Bcl-x L , respectively.
We then tested whether targeting of Bcl-2 and Bcl-x L by the miR-15 family and let-7a contributes to Myc-induced apoptosis, independent of p53. MycV394D-ER was activated in p53-null MEFs under reduced serum conditions with or without Target Protectors. MycV394D-ERactivated MEFs containing Target Protectors had increased cell expansion and reduced cleaved Caspase-3 and AnnexinV-positivity (Fig. 7D-F) . Thus, Myc induces the expression of miR-15 family and let-7a independent of p53, leading to apoptosis. Collectively, the data reveal a novel mechanism whereby Myc up-regulates the miR-15 family and let-7a that target Bcl-2 and Bcl-x L in untransformed cells to trigger apoptosis, and that this mechanism is re-activated in lymphomas following HDACi.
Discussion
Although selective killing of tumor cells by HDACi is being clinically tested and multiple effects have been noted, such as altered expression of apoptotic genes and DNA damage However, they reported down-regulation of let-7a, whereas we detected increased let-7a upon HDACi; this discrepancy may be due to differences in the cell types evaluated or the HDAC inhibitors used. Importantly, our results indicate HDACi-induced changes in Bcl-2 and Bcl-x L were mediated by Myc. Myc is overexpressed and/or dysregulated in most human malignancies and is essential in cancers driven by other oncogenes, such as mutant Ras (4, 41) . Thus, our data, providing a molecular link between Myc, miRNA, and Bcl-2 and Bcl-x L , yield new insights into CAN-15-1751 the transforming action of Myc, and suggest how this pathway can be targeted therapeutically.
Moreover, our work suggests the expression of these miRNA may be useful biomarkers for HDACi sensitivity.
Due to previous reports that Myc repressed miRNA in malignant cells (14, 26) , we were initially surprised when Myc induced the expression of the miR-15 family and let-7a in untransformed cells. However, Myc overexpression drives cancer cell proliferation, but triggers apoptosis in untransformed cells (4) . Myc induces apoptosis by activating the p53 pathway and simultaneously down-regulating Bcl-2 and Bcl-x L mRNA expression through an indirect mechanism (7, 8) , reportedly involving Miz-1 (9). Myc expression did not change the half-life of Bcl-2 (7); therefore, we suspected a transcriptional or post-transcriptional mechanism. The miR-15 family and let-7a were known to target Bcl-2 and Bcl-x L , respectively, contributing to apoptosis (25), so we investigated whether a connection between Myc, these miRNA, and Bcl-2 Moreover, Myc is reported to recruit HDAC3 to the promoters of protein-coding genes and miRNA to repress their expression (12, 40, 44) . However, RGFP233, the HDAC1/2 inhibitor, also increased levels of miR-15a and let-7a, indicating they may also contribute to the repression. Furthermore, hematopoietic cell lines with either mutant or wild-type p53 showed analogous results, indicating HDACi-induced effects are independent of p53 status. Given the p53 pathway is inactivated and Myc is dysregulated in most human cancers (4, 45) , our results identify a new potentially therapeutic avenue to induce apoptosis that capitalizes on Myc and is independent of p53. Of note, overexpression of Bcl-2 and/or Bcl-x L protected from HDACiinduced cell death (46-49), supporting our conclusion that miRNA targeting these genes leads to apoptosis. Our studies have identified a novel mechanism of Myc-induced apoptosis that capitalizes on miRNA to suppress the expression of crucial pro-survival proteins. While this mechanism is inactivated in malignancies through epigenetic alterations involving HDACs, we have shown it can be reactivated by HDACi. Our current study provides a novel mechanism that underlies HDACi-mediated cell death and offers new insights that should aid in improving cancer therapies. 
